Rucker JJH, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. 2018;142:20018. <\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Vollenweider FX, Smallridge JW. Classic psychedelic drugs: update on biological mechanisms. Pharmacopsychiatry. 2022;55:12138. <\/p>\n
Article PubMed PubMed Central Google Scholar <\/p>\n
Lpez-Gimnez JF, Gonzlez-Maeso J. Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Curr Top Behav Neurosci. 2018;36:45. <\/p>\n
Article PubMed PubMed Central Google Scholar <\/p>\n
Mendes FR, dos Santos Costa C, Wiltenburg VD, Morales-Lima G, Fernandes JAB, Filev R. Classic and nonclassic psychedelics for substance use disorder: a review of their historic, past and current research. Addict Neurosci. 2022;3:100025. <\/p>\n
Article Google Scholar <\/p>\n
Dai R, Larkin TE, Huang Z, Tarnal V, Picton P, Vlisides PE, et al. Classical and non-classical psychedelic drugs induce common network changes in human cortex. Neuroimage. 2023;273:120097. <\/p>\n
Article PubMed Google Scholar <\/p>\n
Inserra A. Hypothesis: the psychedelic ayahuasca Heals traumatic memories via a sigma 1 receptor-mediated epigenetic-mnemonic process. Front Pharmacol. 2018;9:330. <\/p>\n
Article PubMed PubMed Central Google Scholar <\/p>\n
Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Pont KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34:15566. <\/p>\n
Article PubMed Google Scholar <\/p>\n
Glintborg C, Thomsen AS, Hansen TGB. Beyond broken bodies and brains: a mixed methods study of mental health and life transitions after brain injury. Brain Impairment. 2018;19:21527. <\/p>\n
Article Google Scholar <\/p>\n
Hiplito I, Mago J, Rosas FE, Carhart-Harris R. Pattern breaking: a complex systems approach to psychedelic medicine. PsyArXiv. https:\/\/doi.org\/10.31234\/OSF.IO\/YDU3H<\/a> (2023). <\/p>\n Goodwin GM, Aaronson ST, Dunlop BW, Feifel D, Hellerstein DJ, Hewitt N, et al. The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a phase IIb randomised controlled trial. Neurosci Appl. 2022;1:100511. <\/p>\n Article Google Scholar <\/p>\n Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: a systematic review. J Affect Disord. 2019;258:1124. <\/p>\n Article PubMed Google Scholar <\/p>\n Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E. Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol. 2020;23:385. <\/p>\n Article CAS PubMed PubMed Central Google Scholar <\/p>\n Johnson MW. Classic psychedelics in addiction treatment: the case for psilocybin in tobacco smoking cessation. Curr Top Behav Neurosci. 2022;56:21327. <\/p>\n Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67:173540. <\/p>\n Article CAS PubMed Google Scholar <\/p>\n Foldi CJ, Liknaitzky P, Williams M, Oldfield BJ. Rethinking therapeutic strategies for anorexia nervosa: insights from psychedelic medicine and animal models. Front Neurosci. 2020;14:43. <\/p>\n Article PubMed PubMed Central Google Scholar <\/p>\n Zeifman RJ, Singhal N, dos Santos RG, Sanches RF, de Lima Osrio F, Hallak JEC, et al. Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial. Psychopharmacology. 2021;238:4539. <\/p>\n Article CAS PubMed Google Scholar <\/p>\n Johnston JN, Kadriu B, Allen J, Gilbert JR, Henter ID, Zarate CA. Ketamine and serotonergic psychedelics: an update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Neuropharmacology. 2023;226:109422. <\/p>\n Hibicke M, Landry AN, Kramer HM, Talman ZK, Nichols CD. Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression. ACS Appl Mater Interfaces. 2020. https:\/\/doi.org\/10.1021\/ACSCHEMNEURO.9B00493\/SUPPL_FILE\/CN9B00493_LIVESLIDES.MP4<\/a>. <\/p>\n Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022. https:\/\/doi.org\/10.1001\/JAMAPSYCHIATRY.2022.2096<\/a>. <\/p>\n Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018;235:399408. <\/p>\n Article CAS PubMed Google Scholar <\/p>\n Magaraggia I, Kuiperes Z, Schreiber R. Improving cognitive functioning in major depressive disorder with psychedelics: a dimensional approach. Neurobiol Learn Mem. 2021;183:107467. <\/p>\n Article CAS PubMed Google Scholar <\/p>\n Sayal C, Barrett FS. The costs and benefits of psychedelics on cognition and mood. Neuron 2023;111:61430. <\/p>\n Article PubMed Google Scholar <\/p>\n Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, et al. The therapeutic potential of psilocybin. Molecules. 2021;26:2948. <\/p>\n Article CAS PubMed PubMed Central Google Scholar <\/p>\n Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:102533. <\/p>\n Article CAS PubMed PubMed Central Google Scholar <\/p>\n Berger JJ, Fitzgerald PB. The prescription of psychedelic therapies in Australia and New Zealand: a brief survey of psychiatrists. Australas Psychiatry. 2023;31:190. <\/p>\n Article PubMed PubMed Central Google Scholar <\/p>\n Grover C, Monds L, Montebello M. A survey of Australian psychiatrists and psychiatry trainees knowledge of and attitudes towards psychedelics in the treatment of psychiatric disorders. Australas Psychiatry. 2023;31:32935. <\/p>\n Article PubMed Google Scholar <\/p>\n Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 2018;30:36375. <\/p>\n Article PubMed Google Scholar <\/p>\n Thompson C, Szabo A. Psychedelics as a novel approach to treating autoimmune conditions. Immunol Lett. 2020;228:4554. <\/p>\n Article CAS PubMed Google Scholar <\/p>\n de Vos CMH, Mason NL, Kuypers KPC. Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics. Front Psychiatry. 2021;12:1575. <\/p>\n Google Scholar <\/p>\n Ly C, Greb AC, Vargas MV, Duim WC, Grodzki ACG, Lein PJ, et al. Transient stimulation with psychoplastogens is sufficient to initiate neuronal growth. ACS Pharmacol Transl Sci. 2021;4:45260. <\/p>\n Article CAS PubMed Google Scholar <\/p>\n Arciniegas DB. Addressing neuropsychiatric disturbances during rehabilitation after traumatic brain injury: current and future methods. 2022;13:32545. https:\/\/doi.org\/10.31887\/DCNS2011132\/darciniegas<\/a>. <\/p>\n Bramlett HM, Dietrich WD. Long-term consequences of traumatic brain injury: current status of potential mechanisms of injury and neurological outcomes. J Neurotrauma. 2015;32:1834. <\/p>\n Article PubMed PubMed Central Google Scholar <\/p>\n Khan SM, Carter GT, Aggarwal SK, Holland J. Psychedelics for brain injury: a mini-review. Front Neurol. 2021;12:1260. <\/p>\n Article Google Scholar <\/p>\n Mallah K, Couch C, Borucki DM, Toutonji A, Alshareef M, Tomlinson S. Anti-inflammatory and neuroprotective agents in clinical trials for CNS disease and injury: where do we go from here? Front Immunol. 2020;11:2021. <\/p>\n Article CAS PubMed PubMed Central Google Scholar <\/p>\n Feigin VL, Barker-Collo S, Krishnamurthi R, Theadom A, Starkey N. Epidemiology of ischaemic stroke and traumatic brain injury. Best Pract Res Clin Anaesthesiol. 2010;24:48594. <\/p>\n Article PubMed Google Scholar <\/p>\n Xu XJ, Yang MS, Zhang B, Niu F, Dong JQ, Liu BY. Glucose metabolism: a link between traumatic brain injury and Alzheimers disease. Chin J Traumatol. 2021;24:5. <\/p>\n Article PubMed Google Scholar <\/p>\n Lu J, Goldman L, Siddiqui EM, Khan A, Jahan S, Rehman MU, et al. Understanding acquired brain injury: a review. Biomedicines. 2022;10:2167. <\/p>\n Article Google Scholar <\/p>\n Dewan MC, Rattani A, Gupta S, Baticulon RE, Hung YC, Punchak M, et al. Estimating the global incidence of traumatic brain injury. J Neurosurg. 2018;130:108097. <\/p>\n Article PubMed Google Scholar <\/p>\n Voss JD, Connolly J, Schwab KA, Scher AI. Update on the epidemiology of concussion\/mild traumatic brain injury. Curr Pain Headache Rep. 2015;19:18. <\/p>\n Article Google Scholar <\/p>\n Donkor ES. Stroke in the 21st century: a snapshot of the burden, epidemiology, and quality of life. Stroke Res Treat. 2018;2018:3238165. <\/p>\n Strilciuc S, Grad DA, Radu C, Chira D, Stan A, Ungureanu M, et al. The economic burden of stroke: a systematic review of cost of illness studies. J Med Life. 2021;14:606. <\/p>\n Article PubMed PubMed Central Google Scholar <\/p>\n Lund SB, Gjeilo KHKH, Moen KG, Schirmer-Mikalsen K, Skandsen T, Vik A. Moderate traumatic brain injury, acute phase course and deviations in physiological variables: an observational study. Scand J Trauma Resusc Emerg Med. 2016;24:18. <\/p>\n Article Google Scholar <\/p>\n Schimmel S, Acosta S, Lozano D. Neuroinflammation in traumatic brain injury: a chronic response to an acute injury. Brain Circ. 2017;3:135. <\/p>\n Article PubMed PubMed Central Google Scholar <\/p>\n Chugh C. Acute ischemic stroke: management approach. Indian J Crit Care Med. 2019;23:S140. <\/p>\n Article PubMed PubMed Central Google Scholar <\/p>\n Ponsford J, Nguyen S, Downing M, Bosch M, McKenzie JE, Turner S, et al. Factors associated with persistent post-concussion symptoms following mild traumatic brain injury in adults. J Rehabil Med. 2019;51:3239. <\/p>\n Article PubMed Google Scholar <\/p>\n Nelson LD, Temkin NR, Dikmen S, Barber J, Giacino JT, Yuh E, et al. Recovery after mild traumatic brain injury in patients presenting to US level I trauma centers: a transforming research and clinical knowledge in traumatic brain injury (TRACK-TBI) study. JAMA Neurol. 2019;76:104959. <\/p>\n Article PubMed PubMed Central Google Scholar <\/p>\n Lee B, Bennett LL, Bernick C, Shan G, Banks SJ. The relations among depression, cognition, and brain volume in professional boxers: a preliminary examination using brief clinical measures. J Head Trauma Rehabil. 2019;34:E29E39. <\/p>\n Article PubMed Google Scholar <\/p>\n Major B, Symons GF, Sinclair B, OBrien WT, Costello D, Wright DK, et al. White and gray matter abnormalities in Australian footballers with a history of sports-related concussion: an MRI study. Cereb Cortex. 2021;31:53318. <\/p>\n Article PubMed Google Scholar <\/p>\n Wright DK, Symons GF, OBrien WT, McDonald SJ, Zamani A, Major B, et al. Diffusion imaging reveals sex differences in the white matter following sports-related concussion. Cereb Cortex. 2021;31:44119. <\/p>\n Article PubMed Google Scholar <\/p>\n Costello K, Greenwald BD. Update on domestic violence and traumatic brain injury: a narrative review. Brain Sci. 2022;12:122. <\/p>\n Mans K, Kettner H, Erritzoe D, Haijen ECHM, Kaelen M, Carhart-Harris RL. Sustained, multifaceted improvements in mental well-being following psychedelic experiences in a prospective opportunity sample. Front Psychiatry. 2021;12:1038. <\/p>\n Article Google Scholar <\/p>\n Schmid Y, Liechti ME. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology. 2018;235:535. <\/p>\n Article CAS PubMed Google Scholar <\/p>\n Hackett ML, Pickles K. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke. 2014;9:101725. <\/p>\n Article PubMed Google Scholar <\/p>\n Ayerbe L, Ayis S, Wolfe CDA, Rudd AG. Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br J Psychiatry. 2013;202:1421. <\/p>\n Article PubMed Google Scholar <\/p>\n <\/p>\n View post: <\/p>\n Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential | Molecular ... - Nature.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Rucker JJH, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future Continue reading